Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CTMX SEC filings page on Stock Titan provides access to CytomX Therapeutics, Inc. regulatory documents as filed with the U.S. Securities and Exchange Commission. CytomX is a clinical-stage, oncology-focused biopharmaceutical company whose common stock trades on the Nasdaq Global Select Market under the symbol CTMX. Its filings offer detailed information on financial performance, risk factors, and the status of its development programs based on its PROBODY® therapeutic platform.
Investors can use this page to locate periodic reports and current reports on Form 8-K. For example, the company has filed 8-K reports to furnish quarterly financial results and to describe material events, such as updates on the CX-2051 Phase 1 study in colorectal cancer. These filings may discuss revenue from collaborations, research and development expenses, cash and investments, and other financial metrics, as well as narrative business updates.
The filings also provide context on clinical and safety disclosures. In one 8-K, CytomX reported an update on the CTMX-2051-101 Phase 1 study, including enrollment across multiple dose levels of CX-2051 and a treatment-related adverse event, along with the Safety Review Committee’s support for continued study execution. Such documents help readers understand how the company reports clinical progress and safety oversight in an official regulatory format.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that can help explain complex sections, highlight key points from lengthy reports, and surface items related to topics such as clinical trial status, collaboration revenues, or liquidity. Users interested in CytomX’s oncology pipeline, including varsetatug masetecan/CX-2051 and CX-801, can review the underlying filings alongside these AI-generated insights to form their own view of the company’s disclosures.
CytomX Therapeutics reported Q1 2026 revenue of $10.3 million and a net loss of $18.2 million, compared with $50.9 million of revenue and $23.5 million of net income a year earlier. The drop in revenue primarily reflects completion of collaboration performance obligations in 2025.
Cash, cash equivalents and investments rose to $346.7 million as of March 31, 2026, helped by a $250 million equity follow-on offering, giving an expected cash runway to at least the second half of 2028. The company highlighted positive Phase 1 data and completed 40‑patient dose optimization enrollment for its EpCAM ADC Varseta‑M in advanced colorectal cancer, and ongoing development of CX‑801, including a KEYTRUDA® combination study in melanoma.
CytomX Therapeutics, Inc. reported first-quarter 2026 results showing lower collaboration revenue and a return to net loss while strengthening its balance sheet. Revenue was $10.3 million, down from $50.9 million a year earlier, mainly due to completed and terminated collaborations with Bristol Myers Squibb, Amgen and Astellas.
The company recorded a net loss of $18.2 million, compared with net income of $23.5 million in the prior-year quarter, as revenue fell while research and development and general and administrative expenses remained roughly stable at $19.2 million and $10.7 million, respectively. Varseta-M (EpCAM ADC) was the largest R&D spend at $7.8 million, reflecting its role as the lead program.
CytomX raised significant capital through a March 2026 underwritten offering, issuing 45.99 million shares and 1.18 million pre-funded warrants for $234.2 million in net proceeds. As of March 31, 2026, it held $28.8 million in cash and cash equivalents and $317.9 million in short-term U.S. Treasury investments, giving total assets of $359.4 million and stockholders’ equity of $319.9 million.
CytomX Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026. Proposals include electing two Class II directors, ratifying Ernst & Young LLP as auditor, and amending the charter to increase authorized common stock from 300,000,000 to 600,000,000 shares.
Stockholders are also asked to approve adding 6,500,000 shares to the 2015 Equity Incentive Plan and 1,000,000 shares to the Employee Stock Purchase Plan, plus advisory votes on executive pay and the frequency of future say‑on‑pay votes. Only holders of 217,702,919 shares outstanding as of April 20, 2026 may vote.
CytomX Therapeutics is soliciting proxies for its virtual 2026 Annual Meeting on June 17, 2026 with a record date of April 20, 2026. The meeting agenda includes seven proposals: election of two Class II directors (Matthew P. Young and Elaine V. Jones, Ph.D.), ratification of Ernst & Young LLP as auditor, a Charter Amendment to increase authorized common stock from 300,000,000 to 600,000,000, an increase of 6,500,000 shares to the Amended and Restated 2015 Equity Incentive Plan, and a 1,000,000 share increase to the Employee Stock Purchase Plan (ESPP). The proxy materials state 217,693,878 shares outstanding and 82,306,122 authorized but unissued common shares as of March 31, 2026. The Board recommends votes "For" all proposals.
CytomX Therapeutics reports a Schedule 13G showing Point72-affiliated holders beneficially own 10,864,581 shares of Common Stock, representing 5.0% of the class as of the close of business on April 15, 2026. The filing states the 216,177,309 shares outstanding figure is the sum of 45,990,567 shares issued in a March 18, 2026 offering and 170,186,742 shares outstanding as of February 28, 2026.
The statement is filed jointly by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen under a Joint Filing Agreement and cites shared voting and dispositive power over the reported shares.
CytomX Therapeutics Inc schedule amendment shows The Vanguard Group reports 0 shares beneficially owned of Common Stock and 0% ownership as of 03/13/2026. The filing explains an internal realignment at The Vanguard Group that caused disaggregated reporting by subsidiaries.
CytomX Therapeutics Chief Medical Officer Yu‑Waye Chu reported an open-market sale of 21,279 shares of common stock at $6.423 per share. According to the filing, the shares were sold solely to cover tax and other government withholding obligations tied to vesting restricted stock units. After this transaction, Chu directly holds 189,446 shares, which includes 149,833 RSUs that may settle in stock as they vest.
CytomX Therapeutics CEO Sean A. McCarthy reported a tax-driven share sale. He sold 118,969 shares of common stock on March 17, 2026 at an average price of $6.423 per share, solely to satisfy tax and other government withholding obligations linked to vesting restricted stock units.
After this transaction, he directly holds 1,078,922 common shares, which include 457,500 RSUs, and indirectly holds 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee. The filing shows no remaining derivative securities such as stock options or warrants.
CytomX Therapeutics, Inc. executive Marcia Belvin, SVP and Chief Scientific Officer, reported an open-market sale of 31,492 shares of common stock on March 17, 2026 at $6.423 per share. The sale was made solely to satisfy tax or other government withholding obligations tied to vesting restricted stock units (RSUs).
After this transaction, Belvin directly holds 300,760 shares of common stock, which includes 135,833 RSUs. This filing reflects a compensation-related tax obligation rather than a discretionary portfolio trade.
CytomX Therapeutics, Inc. Chief Financial Officer Christopher Ogden sold 19,323 shares of common stock at an average price of $6.423 per share. The sale was made solely to satisfy tax and other government withholding obligations related to vesting restricted stock units. After this transaction, he directly holds 296,948 shares of common stock, which includes 173,082 restricted stock units.